ArticleApplied biochemistry and biotechnology2026
MAFB Overexpression in Macrophages Promotes Wound Healing in Diabetic Foot Ulcer by Transcriptionally Activating WDR74 to Drive a Tissue-Repair Phenotype and Suppress Inflammation and Oxidative Stress.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcer (DFU) represents a significant challenge in clinical management due to its complexity and the impaired wound-healing process associated with diabetes. The role of MAF bZIP transcription factor B (MAFB) in regulating macrophage polarization and its potential impact on DFU healing is an area of growing interest. This study investigates the molecular mechanisms by which MAFB influences diabetic wound healing. MAFB and WD repeat domain 74 (WDR74) protein levels were evaluated using western blotting. mRNA expression of target genes was quantified through quantitative real-time polymerase chain reaction. Flow cytometry was utilized to analyze the proportion of cluster of differentiation 206 (CD206) and CD86-positive cells. Enzyme-linked immunosorbent assays were conducted to measure the concentrations of interleukin-6, tumor necrosis factor-alpha, and interleukin-10. Malondialdehyde production and superoxide dismutase activity were determined using colorimetric assays. Reactive oxygen species levels were quantified with a fluorometric assay. Chromatin immunoprecipitation and dual-luciferase reporter assays were performed to examine the interaction between MAFB and WDR74. Furthermore, a rat model of DFU was established to validate in vivo findings regarding MAFB's role in M2 polarization, inflammation, and oxidative stress. Histological evaluation of wound tissues was performed using hematoxylin and eosin (H&E)and Masson's trichrome staining. The results showed that elevated MAFB levels in LPS-stimulated RAW264.7 macrophages led to a shift towards an M2 phenotype, alongside decreased inflammatory responses and oxidative stress. Mechanistically, MAFB was found to activate the transcription of WDR74 in these macrophages. Notably, WDR74 upregulation promoted M2 polarization and mitigated inflammation and oxidative stress in LPS-treated cells, whereas silencing WDR74 reversed the beneficial effects of MAFB overexpression. Further, in vivo, MAFB promoted wound healing of DFU rats by repressing inflammatory and oxidative stress responses. Thus, MAFB overexpression promoted diabetic foot ulcer healing by fostering a tissue repair phenotype and suppressing inflammation and oxidative stress through the transcriptional activation of WDR74. These findings underscore the potential of MAFB as a therapeutic target for improving diabetic wound healing, which could lead to novel clinical strategies for treating DFUs.
Indexed as
Identifiers
42360661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.